While the P3 data might help them target patients that will benefit most, Glufo needs to prove itself as a combo therapy to be a big winner. Sooner or later someone is going to come up with a "traditional" chemo agent that is better than Gemzar in treating pancreatic cancer - hopefully by then, Glufo will be part of the standard first-line treatment, and the new agent will be combined with Glufo. The same can be said of the other solid cancer indications - we need Glufo (or TH302) to be part of a combo therapy treatement regime!
TH302: I'm hoping no news is good news: If time goes by without hearing that TH302 is not working in any cycle, could one assume it IS working?
I agree with what you say re: G+G and the G, but this is really outstanding in itself that P3 was not a complete waste. I wonder how much data they can use from sub groups to reduce costs with pursuing further study.